Trial-Results center  
Clinical trial results database Feedback    Home

Related trials

Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin

RE-COVER, 2009 - dabigatran vs vitamin K antagonists

Romera, 2009 - Tinzaparin vs acenocoumarol

Gonz�lez-Fajardo, 2008 - Enoxaparin vs coumarin

Botticelli DVT, 2008 - apixaban vs heparin/VKA

Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA

VanGogh DVT, 2007 - idraparinux vs heparin/VKA

VanGogh PE, 2007 - idraparinux vs heparin/VKA

Daskalopoulos, 2005 - LMWH at home vs UFH in hospital

Fiessinger , 2005 - ximelagatran vs vitamin K antagonists

Chong, 2005 - LMWH at home vs UFH in hospital

Kearon, 2004 - 4 months vs 3 months

Ramacciotti, 2004 - LMWH at home vs UFH in hospital

MATISSE, 2004 - fondaparinux vs enoxaparin

Lee, 2003 - Dalteparin vs warfarin

Agnelli, 2003 - 6-12 months vs 3 months

Kakkar, 2003 - Bemiparin vs warfarin

Deitcher, 2003 - Enoxaparin vs warfarin

MATISSE PE, 2003 - fondaparinux vs heparin/VKA

Hull, 2002 - Tinzaparin vs warfarin

Meyer, 2002 - Enoxaparin vs warfarin

Agnelli, 2001 - 12 months vs 3 months

Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH

Lopez-Beret, 2001 - Nadroparin vs acenocoumarol

Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin

See also:

  • All venous thrombosis clinical trials

    Agnelli study, 2003


    Studied treatment continuation for 3 or 9 additionnal months of warfarin or other oral anticoagulant was adjusted to achieve a target INR between 2.0 and 3.0.
    Control treatment discontinuation (after 3 months)


    Inclusion criteria patients ranging from 15 to 85 years of age with a first episode of symptomatic, objectively confirmed pulmonary embolism who had completed 3 uninterrupted months of oral anticoagulant therapy without having a recurrence of bleedingowerpo
    Exclusion criteria prolonged anticoagulant therapy for reasons other than venous thromboembolism;major psychiatric disorders; life expectancy shorter than two years;
    Baseline characteristics
    time of randomization 3 months 

    Method and design

    Randomized effectives NA / NA (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 33 months
    Lost to follow-up NA
    Number of centre 19
    Geographic area Italy
    Primary endpoint Recurrence of symptomatic confirmed VTE./pj


    No results available for this trial - no clinical endpoint reported


    Trials register # NA
    • Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P. Extended oral anticoagulant therapy after a first episode of pulmonary embolism.. Ann Intern Med 2003;139:19-25
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend